Bachem Holding AG Class B (BCHMF)
OTHER OTC:BCHMF
BCHMF Stock Chart & Stats
$89.59
--
Market closed
$89.59
--
Day’s Range― - ―
52-Week Range$58.30 - $108.92
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
$6.21B
Enterprise Value$5.05B
Total Cash (Recent Filing)$30.99M
Total Debt (Recent Filing)$57.39M
Price to Earnings (P/E)33.6
Beta1.30
Next Earnings
Jul 30, 2026EPS Estimate
0.51Next Dividend Ex-DateN/A
Dividend Yield1.45%
Share Statistics
EPS (TTM)1.99
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio1.27
Price to Book (P/B)3.08
Price to Sales (P/S)6.46
P/FCF Ratio-93.15
Enterprise Value/Market Cap0.81
Enterprise Value/Revenue7.27
Enterprise Value/Gross Profit25.31
Enterprise Value/Ebitda28.11
Forecast
1Y Price Target
$107.25Price Target Upside19.71% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)2.93
Revenue Forecast (FY)$1.18B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetExtremely low leverage and a growing equity base provide durable financial resilience, reducing refinancing and interest-rate risk. This conservatism supports sustained investment in capacity, secures long-term supply commitments, and preserves optionality for M&A or cyclical downturns.
Specialized CDMO Business ModelA focused CDMO model for peptide/oligonucleotide APIs creates structural demand from pharma/biotech customers, with high switching costs and regulatory barriers. Long product lifecycles and supply agreements make revenue streams sticky and support long-term contract renewals and commercialization volumes.
Steady Revenue Growth And Solid MarginsConsistent top-line expansion and a healthy ~21% net margin indicate a resilient earnings profile. Sustainable profitability supports reinvestment in capacity and R&D, enabling the company to capture new commercial-scale contracts and maintain competitive manufacturing capability over several quarters.
Bears Say
Persistent Negative Free Cash FlowOngoing negative free cash flow implies heavy capex or working-capital absorption, which limits internal funding for dividends, share buybacks, or opportunistic M&A. Over months, this can force reliance on external financing or slow organic reinvestment if cash conversion does not improve.
Uneven Cash ConversionInconsistent conversion of net income into operating cash reduces the predictability of cash available for capital allocation. For a manufacturing-focused CDMO, this variability complicates planning for capacity expansions and may increase dependence on short-term working capital financing.
Gradual Margin Compression RiskA gradual erosion of margins versus earlier peaks suggests pressure from costs, pricing, or a shift in business mix toward lower-margin work. If structural, this trend can erode return on invested capital and reduce the long-term cash-generating power of the core CDMO franchise.
Bachem Holding AG News
BCHMF FAQ
What was Bachem Holding AG Class B’s price range in the past 12 months?
Bachem Holding AG Class B lowest stock price was $58.30 and its highest was $108.92 in the past 12 months.
What is Bachem Holding AG Class B’s market cap?
Bachem Holding AG Class B’s market cap is $6.21B.
When is Bachem Holding AG Class B’s upcoming earnings report date?
Bachem Holding AG Class B’s upcoming earnings report date is Jul 30, 2026 which is in 37 days.
How were Bachem Holding AG Class B’s earnings last quarter?
Bachem Holding AG Class B released its earnings results on Mar 12, 2026. The company reported $1.658 earnings per share for the quarter, beating the consensus estimate of $1.159 by $0.499.
Is Bachem Holding AG Class B overvalued?
According to Wall Street analysts Bachem Holding AG Class B’s price is currently Undervalued.
Does Bachem Holding AG Class B pay dividends?
Bachem Holding AG Class B pays a Annually dividend of $0.575 which represents an annual dividend yield of 1.45%. See more information on Bachem Holding AG Class B dividends here
What is Bachem Holding AG Class B’s EPS estimate?
Bachem Holding AG Class B’s EPS estimate is 0.51.
How many shares outstanding does Bachem Holding AG Class B have?
Currently, no data Available
What happened to Bachem Holding AG Class B’s price movement after its last earnings report?
Bachem Holding AG Class B reported an EPS of $1.658 in its last earnings report, beating expectations of $1.159. Following the earnings report the stock price went up 8.803%.
Which hedge fund is a major shareholder of Bachem Holding AG Class B?
Currently, no hedge funds are holding shares in BCHMF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bachem Holding AG Class B
Bachem Holding AG serves pharmaceutical and biotechnology companies globally, providing products crucial for research, clinical development, and commercial use. The company's primary focus is on the design, manufacturing, and regulatory support for peptide active pharmaceutical ingredients (APIs), specifically targeting novel peptide and oligonucleotide chemical entities (NCEs). Additionally, Bachem offers commercially available NCEs and generic compounds. Its comprehensive service portfolio includes project management, quality assurance and regulatory guidance, analytical testing, production adhering to Good Manufacturing Practices (GMP), manufacturing for research purposes, and expertise in supply chain and vertical integration. Established in 1971, Bachem Holding AG is headquartered in Bubendorf, Switzerland, and functions as a subsidiary of Ingro Finanz AG.
BCHMF Stock 12 Month Forecast
Average Price Target
$107.25
▲(19.71% Upside)
Ownership Overview
―
Insiders
1.25% Mutual Funds
― Other Institutional Investors
96.42% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---